Compare ACADIA Pharmaceuticals Inc. (ACAD) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs J M Smucker Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while J M Smucker Co trades at $112.65 (market cap $12.10B). The key difference: J M Smucker Co is far larger — about 2.7× ACADIA Pharmaceuticals Inc.'s market cap, and J M Smucker Co pays a 3.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SJM | |
|---|---|---|
Market Cap | $4.49B | $12.10B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $117.05 |
52-Week Low | $20.06 | $89.53 |
Enterprise Value | $3.69B | $19.13B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
J.M. Smucker (SJM) trades at $113.24, down 2.61% on the day, with a bullish technical signal from moving averages. The company reported mixed Q4 2026 results, beating EPS estimates but facing sales pressure, with fiscal 2027 revenue guidance projecting a 3-4% decline. Strong cash flow supports a sustainable 4% dividend yield, while valuation metrics show a P/E of 22.05 and P/S of 1.32.
SJM presents a value opportunity with analyst consensus at $122.92 (8.5% upside), but faces headwinds from weak sales visibility and portfolio challenges. The stock's outlook hinges on Uncrustables growth and coffee margin recovery, with balanced risks between dividend stability and competitive pressures in packaged foods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
